This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Provention Bio Management
Management criteria checks 3/4
Key information
Ashleigh Palmer
Chief executive officer
US$2.3m
Total compensation
| CEO salary percentage | 29.8% |
| CEO tenure | 6.5yrs |
| CEO ownership | 2.7% |
| Management average tenure | 3.3yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Provention Bio appoints O'Brien as Chief People Officer
Sep 19Provention Bio secures $125M term loan facility
Sep 01Provention Bio: More Risk, More Dilution Ahead - Downgrading To A Sell Rating
Aug 12Provention Bio Q2 2022 Earnings Preview
Aug 03Provention Bio to raise $60M through private placement of securities
Jul 08Provention Bio says FDA extends review period for co's teplizumab application to Nov. 17
Jun 30Provention Bio (PRVB): BLA Accepted; Downgrading To A Hold
Mar 31Provention Bio: Upgrading To A Strong-Buy, Potential Cure For Type 1 Diabetes
Feb 04Is Provention Bio (NASDAQ:PRVB) In A Good Position To Invest In Growth?
Jan 11
Is Provention Bio (NASDAQ:PRVB) In A Good Position To Deliver On Growth Plans?
Aug 26Provention Bio: Blood (Glucose) In The Streets
Jul 30FDA Advisory Committee supports Provention Bio's teplizumab in delaying diabetes
May 28Provention Bio EPS misses by $0.05
May 06Provention Bio provides regulatory update on teplizumab BLA
Apr 27How Much Of Provention Bio, Inc. (NASDAQ:PRVB) Do Insiders Own?
Mar 17Need To Know: Provention Bio, Inc. (NASDAQ:PRVB) Insiders Have Been Buying Shares
Feb 10
Provention Bio prices $100M stock offering
Jan 14Provention Bio Could See Meaningful Upside Once Teplizumab Hits The Market
Jan 07Provention Bio (NASDAQ:PRVB) Is In A Good Position To Deliver On Growth Plans
Jan 06Provention Bio files US application for its diabetes drug
Jan 04Provention Bio launches first-in-human PRV-101 study in coxsackievirus B
Dec 15Is Provention Bio, Inc.'s (NASDAQ:PRVB) Shareholder Ownership Skewed Towards Insiders?
Dec 02Provention Bio EPS misses by $0.14
Nov 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2022 | US$2m | US$675k | -US$114m |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$105m |
| Mar 31 2022 | n/a | n/a | -US$104m |
| Dec 31 2021 | US$2m | US$613k | -US$114m |
| Sep 30 2021 | n/a | n/a | -US$121m |
| Jun 30 2021 | n/a | n/a | -US$125m |
| Mar 31 2021 | n/a | n/a | -US$118m |
| Dec 31 2020 | US$2m | US$595k | -US$99m |
| Sep 30 2020 | n/a | n/a | -US$77m |
| Jun 30 2020 | n/a | n/a | -US$55m |
| Mar 31 2020 | n/a | n/a | -US$45m |
| Dec 31 2019 | US$4m | US$500k | -US$43m |
| Sep 30 2019 | n/a | n/a | -US$38m |
| Jun 30 2019 | n/a | n/a | -US$34m |
| Mar 31 2019 | n/a | n/a | -US$33m |
| Dec 31 2018 | US$584k | US$425k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$25m |
| Jun 30 2018 | n/a | n/a | -US$21m |
| Mar 31 2018 | n/a | n/a | -US$15m |
| Dec 31 2017 | US$778k | US$290k | -US$9m |
Compensation vs Market: Ashleigh's total compensation ($USD2.27M) is below average for companies of similar size in the US market ($USD5.37M).
Compensation vs Earnings: Ashleigh's compensation has increased whilst the company is unprofitable.
CEO
Ashleigh Palmer (59 yo)
6.5yrs
Tenure
US$2,266,108
Compensation
Mr. Ashleigh W. Palmer, B.Sc., M.B.A., is Co-Founder, President, Chief Executive Officer and Director of Provention Bio, Inc. since October 4, 2016. Mr. Palmer served as Chief Executive Officer and Preside...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.5yrs | US$2.27m | 2.71% $ 64.2m | |
| Co-Founder & Chief Scientific Officer | 6.5yrs | US$1.16m | 1.13% $ 26.8m | |
| Chief Medical Officer | 3.3yrs | US$1.16m | 0.074% $ 1.7m | |
| Chief Financial Officer | 1.3yrs | US$2.24m | no data | |
| Chief Operations Officer | 1.3yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Legal Officer | 2.7yrs | no data | no data | |
| Vice President of Corporate Communications | no data | no data | no data | |
| Vice President Marketing | no data | no data | no data | |
| Chief People Officer | less than a year | no data | no data | |
| Senior Vice President of Clinical Development | 3.7yrs | no data | no data | |
| Chief Commercial Officer | 3.3yrs | US$5.61m | 0% $ 0 |
3.3yrs
Average Tenure
46yo
Average Age
Experienced Management: PRVB's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.5yrs | US$2.27m | 2.71% $ 64.2m | |
| Independent Director | 4.6yrs | US$168.04k | 0.021% $ 499.6k | |
| Independent Director | 2.9yrs | US$159.08k | 0% $ 0 | |
| Independent Chairman | 5yrs | US$198.36k | 0.0079% $ 187.3k | |
| Independent Director | 2.7yrs | US$150.22k | 0% $ 0 | |
| Independent Director | less than a year | no data | no data |
3.8yrs
Average Tenure
64yo
Average Age
Experienced Board: PRVB's board of directors are considered experienced (3.8 years average tenure).